

Special Issue

Advances in Thoracic Oncology: A Multi-disciplinary Approach to Lung Cancer

Message from the Guest Editors

The landscape and treatment options for lung cancer for both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are rapidly evolving. Patients are living longer due to advances in thoracic radiation therapy, immunotherapy, targeted therapy, and thoracic surgery. This Issue on the advances in thoracic oncology will provide a current update and overview, encompassing the role of these advances for both SCLC and NSCLC. We are pleased to include leading researchers that will provide a comprehensive summary and new evidence for the following topics: role of local therapy for brain metastases and prophylactic cranial irradiation in NSCLC and SCLC, thoracic re-irradiation for isolated thoracic recurrences, cardiac toxicities from thoracic radiotherapy and mitigation strategies, neoadjuvant therapy and peri-operative therapy for operable stage III NSCLC, oligometastatic and oligoprogressive lung cancer and the role of local therapy, personalized treatment approaches for frail or older patients with lung cancer, emerging systemic options (targeted therapy and immunotherapy) in lung cancer, and finally advances in the treatment paradigm for unresectable stage III NSCLC.

Guest Editors

Dr. Percy Lee
Dr. Jyoti Malhotra
Dr. Arya Amini

Deadline for manuscript submissions

closed (31 August 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/197633

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)